Recently approved direct-acting antiviral (DAA) regimens can safely and effectively treat hepatitis C without interferon, with cure rates often exceeding 95%, according to a recently published review. “Oral DAA regimens that are highly efficacious, well-tolerated, and relatively short in duration are now available for all [hepatitis C virus] genotypes and for patient populations historically considered
Biomarkers of liver injury may persist after hepatitis C treatment
A biomarker of liver damage may persist after hepatitis C treatment: About one-third of patients who were successfully treated to eliminate the hepatitis C virus continued to exhibit liver inflammation, a German study showed. The findings include people who took direct-acting antiviral (DAA) drugs, the current preferred therapy for the virus. “This is the first
